StemCell Therapy

August 11, 2017 - By Linda Rogers

Aug 11 is a positive day so far for BioShares Biotechnology Clinical Trials (NASDAQ:BBC) as the ETF is active during the day after gaining 1.42% to hit $23.65 per share. The exchange traded fund has 23.44 million net assets and 2.75% volatility this month.

Over the course of the day 619 shares traded hands, as compared to an average volume of 11,600 over the last 30 days for BioShares Biotechnology Clinical Trials (NASDAQ:BBC).

The ETF is -32.38% of its 52-Week High and 35.06% of its low, and is currently having ATR of 0.74. This years performance is -25.34% while this quarters performance is 2.78%.

The ETFs YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.

More notable recent BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) news were published by: Marketwatch.com which released: BioShares Biotechnology Clinical Trials Fund on December 16, 2014, also Etfdailynews.com with their article: This Tiny Early-Stage Biotech ETF Was Q1s Best Performing Fund published on March 31, 2017, Globenewswire.com published: BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition on June 16, 2017. More interesting news about BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) were released by: Forbes.com and their article: A More Viable Way To Invest In Top-Performing Biotech Stocks published on August 12, 2015 as well as Etftrends.coms news article titled: Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal with publication date: April 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
BioShares Biotechnology Clinical Trials (BBC) Rises 1.42% for Aug 11 - BZ Weekly

Joe Cox, Ph.D., Bolder BioTechnology's President said: "Initiation of this clinical trial represents a major milestone for Bolder BioTechnology and the culmination of many years of effort by our dedicated and talented employees."

"BBT-015 is a novel G-CSF analog that exhibits a longer duration of action and greater potency than other G-CSF products. In preclinical studies, BBT-015 stimulated larger and longer-lasting increases in neutrophils, and faster neutrophil recovery in chemotherapy-treated, neutropenic animals compared to other G-CSF products.BBT-015 also significantly increased survival and accelerated recovery of neutrophils, platelets, and red blood cells in animals exposed to lethal doses of radiation, even when administered 24 hours following radiation exposure."

"BBT-015's increased potency and longer duration of action may stimulate faster neutrophil recovery in cancer patients and / or allow the drug to be administered less frequently and at lower doses than competing G-CSF products, with associated cost savings for patients."

"G-CSF products are some of the best selling biopharmaceuticals in the world, with annual worldwide sales exceeding $6 billion, primarily from the treatment of neutropenia in cancer patients."

About BBT-015BBT-015 is a long-acting G-CSF analog produced using site-specific PEGylation technology.G-CSF is a human protein that stimulates production of neutrophils, a type of white blood cell that is important for fighting infections.G-CSF has a short half-life in humans and typically is administered to patients by daily injection.BBT-015 has been selectively modified with the polymer polyethylene glycol at a unique site in the protein, which allows the protein to last longer in patients, reducing the need for frequent administration and increasing the protein's ability to stimulate long-lasting production of neutrophils.

About Chemotherapy-Related NeutropeniaNeutropenia (severely reduced numbers of neutrophils) is a common side effect of chemotherapy treatment in cancer patients.Neutropenia increases the patient's risk of developing serious bacterial infection and requiring expensive hospitalization.G-CSF products are commonly administered to cancer patients following chemotherapy to accelerate neutrophil recovery and decrease the length of time that patients are neutropenic.

About Acute Radiation SyndromeAcute Radiation Syndrome, often referred to as radiation sickness, is a collection of illnesses that occurs following exposure to high doses of ionizing radiation within a short period of time, such as might occur following an accident at a nuclear power plant or detonation of a nuclear weapon.Bone marrow, which is responsible for producing new blood cells, is one of the most radiation-sensitive tissues, and subjects acutely exposed to high doses of radiation typically develop bone marrow aplasia and severe neutropenia and thrombocytopenia (low numbers of platelets) within a few weeks of exposure, Many subjects die from infections due to a lack of neutrophils, or from uncontrolled bleeding due to a lack of platelets.

About Bolder BioTechnologyBolder BioTechnology, Inc. is a private company that uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at http://www.bolderbio.com.

Government SupportPreclinical research reported in this press release was supported by The National Cancer Institute and The National Institute of Allergy and Infectious Diseases of the National Institutes of Health under awards R43CA078094, R44CA078094, R43AI084288, R44AI084288, andU01AI107340. The content of this press release is solely the responsibility of Bolder BioTechnology and does not necessarily represent the views of the National Institutes of Health.

Forward Looking StatementsStatements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

View original content:http://www.prnewswire.com/news-releases/bolder-biotechnology-announces-initiation-of-phase-1-clinical-trial-of-bbt-015-for-treating-neutropenia-and-acute-radiation-syndrome-300498287.html

SOURCE Bolder BioTechnology, Inc.

http://www.bolderbio.com

Follow this link:
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute ... - PR Newswire (press release)

Puma Biotechnology, Inc. (NASDAQ:PBYI)market capitalization at present is $3.29B at the rate of $89.95 a share. The firms price-to-sales ratio was noted 0.00 in contrast with an overall industry average of 100.62. Most of the active traders and investors are keen to find ways to compare the value of stocks. The price-to-sales ratio offers a simple approach in this case. They just need to take the companys market capitalization and divide it by the companys total sales over the past 12 months. The lesser the ratio, the more attractive the investment. During the key period of last 5 years, Puma Biotechnology, Inc. (NASDAQ:PBYI) earnings per share growth remained at -44.40%.

How Company Returns Shareholders Value?

Dividends is a reward scheme, that a company presents to its shareholders. There can be various forms of dividends, such as cash payment, stocks or any other form. This payment is usually a part of the profit of the company. A companys dividend is mostly determined by its board of directors and it requires the shareholders approval.Puma Biotechnology, Inc. (NASDAQ:PBYI)for the trailing twelve months paying dividend with the payout ratio of 0.00% to its shareholders. Currently it is offering a dividend yield of 0.00% and a 5 year dividend growth rate of 0.00%. Over the last year Companys shares have been trading in the range of $28.35 and $98.85. However yesterday the stock remained in between $83.13 and $93.95. The stock is above its 52-week low with 217.28% and is in the wake of its 52-week high with -9.00%.

Performance & Technicalities

In the latest week Puma Biotechnology, Inc. (NASDAQ:PBYI) stock volatility was recorded 6.05% which for the previous full month was noted 4.93%. Meanwhile the stock weekly performance was subdued at -5.66%, which was upheld for the month at 2.92%. Likewise, the upbeat performance for the last quarter was 130.64% and for the full year it was 83.42%. Moreover the Companys Year To Date performance was 193.00%. Now a days one of the fundamental indicator used in the technical analysis is called Stochastic %D, Stochastic indicator was created by George Lane. The stochastic is a momentum indicator comparing the closing price of a security to the range of its prices over a fix period of time. The gauge is based on the assumption that if price surges, the closing price tends towards the values that belong to the upper part of the area of price movements in the preceding period. On the other hand if price drops, the contrary is right. For Puma Biotechnology, Inc. (NASDAQ:PBYI), Stochastic %D value stayed at 72.69% for the last 9 days. Considering more the value stands at 79.05% and 79.07% for 14 and 20 days, in that order.

Digital Realty Trust, Inc. (NYSE:DLR)closed at $117.59 a share in the latest session and the stock value rose almost 19.67% since the beginning of this year. The company has managed to keep price to sales ratio of 8.23 against an industry average of 10.53. The price to sales ratio is the ratio of the market value of equity to the sales. This ratio is internally not steady, since the market value of equity is divided by the total revenues of the firm. Its revenue stood at 15.10% a year on average in the period of last five years. Firms net income measured an average growth rate of 10.80%. Following last close companys stock, is 2.09% above their SMA 50 and -3.24% below the 52-week high. A simple moving average (SMA) is an mathematical moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods. Its most recent closing price has a distance of 4.77% from SMA20 and is 11.48% above than SMA200.

In-Depth Technical Study

Investors generally keep an extensive variety of technical indicators at their disposal for completing technical stock analysis. The average true range is a moving average, generally 14 days, of the true ranges.

The average true range (ATR) was fashioned to allow traders to more precisely evaluate the daily volatility of an asset by using straightforward calculations. However the indicator does not specify the price direction, rather it is used first and foremost to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

ATR is counted for different periods, like 9-day, 14-day, 20-day, 50-day and 100-day. At the moment, the 14-day ATR for Digital Realty Trust, Inc. (NYSE:DLR) is noted at 2.01.

Continue reading here:
Why Investors remained buoyant on: Puma Biotechnology, Inc. (PBYI), Digital Realty Trust, Inc. (DLR) - StockNewsJournal

20th World Congress on Biotechnology and Biotech Industries Meet during March 05-07, 2018 at London, UK with a theme Future prospects for Biotechnology and Economic Growth. Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Scope and Importance

Biotech Congress 2018 Conference aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotech Congress 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

See more here:
20th World Congress on Biotechnology and Biotech Industries Meet - Technology Networks

HYDERABAD: Dr P M Bhargava, eminent scientist and founder-director of the city-based Centre for Cellular and Molecular Biology (CCMB), died here on Tuesday after a brief illness. He was 89 and is survived by two children.

Pushpa Mittra Bhargava was born on February 22, 1928. He was a pioneer in the field of biotechnology in India and among the first persons to use the term "genetic engineering". Bhargava was instrumental in the formation of the Department of Biotechnology in the '70s. He was also chairman of Medically Aware and Responsible Citizens of Hyderabad, Sambhavna Trust, Bhopal, and Basic Research, Education and Development Society (BREAD), New Delhi. He served as vice-chairman of the National Knowledge Commission between 2005 and 2007.

Bhargava received over 100 national and international honours and awards. He was awarded the Padma Bhushan in 1986 but returned it in 2015 citing "matters of principle". He was honoured with the Legion d'honneur in 1998. He is popularly known as the architect of modern biology in India.

Read the rest here:
Dr Pushpa Mitra Bhargava, pioneer in biotechnology, passes away at 89 - Times of India

The August issue of the New Jersey State Bar Association's bi-monthly magazine, New Jersey Lawyer, focuses on the evolving topic of biotechnology, genetics and the law.

"Although a very specialized area, biotechnology law crosses many legal disciplines, including litigation, licensing, intellectual property, patents, agriculture, business, venture capitalism, antitrust, biosecurity and bioethics," said Angela Foster and David Opderbeck, who served as special editors for the issue.

"The use of biotechnology has raised a number of legal, ethical and social issues, including who owns genetically modified organisms (GMOs), whether genetically modified foods are safe to eat, and who controls a person's genetic information. This issue explores contemporary biotechnology issues impacting the legal community."

A dozen articles explore the topic in the award-winning magazine, beginning with a look at whether organs-on-chips are patentable in an article by Douglas Bucklin. Richard Catalina Jr.'s article on the Biologics Price Competition and Innovation Act follows.

Nancy Del Pizzo's article looks at the open source model in biotechnology, while Foster explores the truth and fiction behind genetically modified food. Jonathan Lourie reviews strategic licenses and collaborations.

Reproduction is the topic of two articles, one analyzing assisted reproductive technology, written by Alan Milstein, and one penned by Kimberly Mutcherson on regulating the right to procreate.

Opderbeck's contribution focuses on synthetic biology and biosecurity, while Anjana Patel and Patricia Wagner discuss biotech mergers, acquisitions and antitrust issues and Marina Sigareva and Ryan O'Donnell look at global strategies for protecting biotech inventions.

The edition closes with articles on the Patent Trial and Appeal Board's influence on the biotech and pharma industries, written by Nichole Valeyko and Maegan Fuller, and the privacy implications for biotechnology by Wagner.

The October edition of New Jersey Lawyer will explore pro bono issues.

Follow this link:
NJSBA magazine explores biotechnology and genetics - Yahoo News

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Privacy Policy (Updated: October 8, 2015):

hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Read the rest here:
NAS Releases Final Report on Preparing for Future Products of Biotechnology - JD Supra (press release)

Investors in Puma Biotechnology, Inc. (PBYI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 28th, 2017, $55 Puthad some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Puma Biotechnology shares, but what is the fundamental picture for the company? Currently, Puma Biotechnology is a Zacks Rank #3 (Hold) in the Medical-Biomed/Genetics industry that ranks in the Bottom 37% of our Zacks Industry Rank. Over the last 60 days, 2 analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from loss of $2.33 per shareto a loss of $2.13 in that period.

Given the way analysts feel about Puma Biotechnology right now, this huge implied volatility could mean theres a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?

Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the TSLA earnings report completely free. See it here: Tesla Earnings Preview with Options Trade Ideas or check out the embedded video below for more details:

More here:
Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock? July 03, 2017 - Zacks.com

Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.

The study conducted at the National Center for Tumor Diseases in Heidelberg (Germany) will investigate the impact of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumors. In addition, Noxxon and Merck & Co will assess safety and efficacy of NOX-A12 in combination with Keytruda (pembrolizumab), Merck & Co./MSDs programmed death receptor-1 (PD-1) immune checkpoint-blocking antibody drug.

The open-label trial (NCT03168139) is composed of two parts: patients will receive NOX-A12 monotherapy for two weeks, followed by combination therapy of NOX-A12 plus pembrolizumab for up to two years. 20 patients will be enroled: 10 patients for each metastatic pancreas and colorectal cancer.

The design of the clinical trial was a collaborative effort between NOXXON and MSD. Part 1 of the study, in which patients will receive NOX-A12 monotherapy for up to two weeks, will evaluate immune infiltrate changes within the tumor microenvironment induced by CXCL12 inhibition with NOX-A12 by comparing pre- and post-treatment biopsy specimens as well as the safety and tolerability of NOX-A12 in patients with metastatic (stage IV) colorectal and pancreatic cancer. Part 2 of the study, in which NOX-A12 is to be combined with Keytruda, will assess the safety and tolerability of the combination in addition to the efficacy of treatment. Top-line data for all 20 patients from part 1 is expected to be available in Q2/2018, and initial response-rate data in Q4/2018.

NOX-A12 inhibits CXCL12, a key tumor microenvironment chemokine and a stem cell migration factor. The chemokine that acts by binding to to CXCR4 and CXCR7 may be a key partner for a wide range of IO (immuno-oncology) agents. Noxxon has generated promising pre-clinical and clinical data, including animal data showing synergy with a checkpoint inhibitor, as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The company said that its study will position the drug to be combined with multiple classes of IO approaches including those acting on or through T cells and/or NK cells.

Read the original post:
Noxxon/MSD start testing of immunoncologic combo - European Biotechnology

News stories about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) have been gaining in popularity quite recently, Accern reports. The analysis company ranks negative and positive press coverage by studying larger than 20 Million SEC financial documents and social media sites sources in real-time. Accern grades analysis of companies ranging from -1 to 1, with ranks nearest to 1 is considered more positive. iShares Nasdaq Biotechnology Index Fund achieved a news impact rank of 0.10 on Accerns range. Accern also gave media analysis about the financial services provider a media impact point of 0 out of 100, indicating that recent press coverage is very unlikely to have an effect on the firms share value next many days.

Stocks of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) started trading at 310.95 on early Tue. the company has 50 Day SMA price of $297.52 and a two hundred SMA of $288.98. iShares Nasdaq Biotechnology Index Fund has a 1 year low of $246.71 and a 1 year high of $323.45.

Few press stories that May have effected Accern trend Analysiss analysis:

Also, the company disclosed a divided for the quarter, to be paid on early Fri, Jun 30th. Traders who own the stock with a record date on Thurs, Jun 29th were given a dividend of $0.1768 for a share. this indicates a $0.71 dividend on a yearly basis and a payout of 0.23%. The ex-dividend date was Tue, Jun 27th.

IBB has been the discussion subject of Quite a few brokerage firm research. Credit Suisse Group boosted iShares Nasdaq Biotechnology Index Fund from a market weight recommendation to an overweight recommendation in a analysis note on Tue, Mar 21st. The move was based on the current stock valulation. crowd sourced stock rating company Vetr boosted iShares Nasdaq Biotechnology Index Fund from a hold recommendation to a buy recommendation and fixed a $300.66 PT on the shares in a study note on early Tue, Apr 18th.

Read more here:
iShares Nasdaq Biotechnology Index Fund (IBB) Earns Slightly Optimistic Media Opinion, Based On A Study - Insider Tradings

Puma Biotechnology, (NYSE:PBYI) is a $3.2 billion market cap company initially focused on developing tyrosine kinase inhibitor neratinib (PB272) for HER2 positive breast cancer. The company has conducted 11 clinical trials for its lead candidate, with over 2,000 patients contributing to a favorable risk-benefit profile, per inflection point clinical trial readouts over the past quarter. Oncologic Drugs Advisory Committee (ODAC) at FDA recently voted for approval of neratinib in HER2 positive extended adjuvant treatment of early stage breast cancer in May 2017. ODAC vote is not binding but carries strong weight in the decision-making process. Given FDA director Gottlieb's new aggressive policies regarding the slow and outdated drug approval process at FDA, this was seen by the market as a "sure thing". The company is advancing neratinib in discussions with EMA for European markets, with validation in August 2016. Other investigations include neratinib in combinatory therapy for metastatic breast cancer and in solid tumors as well.

Neratinib blocks signal cascades of epidermal growth factor receptors or EGFRs, specifically: HER1, HER2, HER3, and HER4. A number of studies are showing nice anti-tumor efficacy. Taken together with ODAC favor, Phase 3 result emphasis for neratinib which met primary endpoints appears to have led to the robust response in the market for high probability of FDA approval. Two-year disease-free survival showed a 2.4% improvement for neratinib versus placebo in ITT population. Five-year disease-free survival showed a 2.5% improvement. In HR+ patients, neratinib adjuvant therapy showed a two-year disease-free survival rate of 95.4% compared to 91.2% in placebo. Five-year disease-free survival conferred a 4.8% benefit. Two-year HR patients' disease-free survival showed a meaningful advantage, but five-year data was not statistically significant.

The company recently presented data June 3 at ASCO 2017 summarizing positive results of its Phase 2 trial in HER2-positive metastatic breast cancer that has metastasized to the brain. Nearly half of the patients in a neratinib plus chemotherapy cohort achieved a central nervous system (CNS) objective response with overall survival data remaining immature at 13.5 months (and counting). CNS progressions remain a huge comorbidity factor in patients with brain metastases. With the ability to cross the blood-brain barrier, and with diarrhea being the number one adverse event, PBYI is well-positioned to advance in this space with neratinib. Studies examining antidiarrheal prophylaxis (Loperamide) to reduce diarrhea severity during neratinib treatment have proven effective. Phase 3 data showed grade 3 diarrhea decreased from ~40% to ~31% with loperamide, to ~23% with loperamide and budesonide, and to 11.5% with loperamide and colestipol. Safety studies examining children and young adults with cancer are also ongoing.

Multiple studies are generating impressive cancer therapy data for neratinib, including clinical data presented at AACR on neratinib in the treatment of patients who have solid tumors with activating HER2 or HER3 mutations. Additional data was also presented on the combination of T-DM1 and neratinib in patients with HER2 positive metastatic breast cancer (MBC) that has previously been treated with pertuzumab and trastuzumab. The company has done extensive analysis of breast cancer NSABP FB-7 biomarker during neratinib treatment with a variety of immuno and chemotherapy regimens to qualify its objective tumor response. Mechanistically, phosphoHER2 levels and truncated HER2 mutants (p95HER2) demonstrated statistically significant higher levels in patients who achieved a pCR with neratinib than those treated with trastuzumab or trastuzumab plus neratinib who did not. Moreover, dual pathway suppression (HR/ER+ and EGFR/HER2+) has been seen only in neratinib and not in Herceptin and Tykerb (Novartis (NYSE:NVS)).

The company has listed other potential tissue types to expand its label for neratinib, including non-small cell lung cancer, colorectal cancer, and solid tumors (any HER2-associated tumors). Roche (OTCQX:RHHBY) annual sales for Herceptin (trastuzumab) approach $5 billion. In contrast, Tykerb has not fared as well due to its unfavorable toxicity profile, with sales in the hundreds of millions. The HER2 positive breast cancer market is estimated to be about $13 billion by 2023. Given this massive market and plenty of room to expand label into other high dollar indications, Puma may still have quite a bit of upside and is generally de-risked. It certainly becomes very attractive on any stock price pullbacks.

Puma reported at end of 1Q 2017 cash and cash equivalents of $105.1 million and marketable securities of $88.9 million, with a 1Q net loss of $72 million. Cash runway is expected to last through mid-2018, with a burn rate of approximately $35 million per quarter. If the company is forced to raise funds, it should be able to do so at a good market value, given the advanced stage of its drug development. Strong Bio recommends a watch list spot for the stock and manageable delays or setbacks as a potential buying opportunity. Moreover, it may be a takeover candidate and could undergo some downward volatility in the standard process of stop-loss triggering. Such swoons will probably not last long as market support should be strong. With market cap of $3 billion and potential market quite a bit larger, there is plenty of room for value position here if sales meet expectations.

Risks for the company to investors are primarily centered around its one-trick pony pipeline. But when the trick is good enough, it's going to bring bank. Its advantage in efficacy will certainly gain a reasonable stake in the market for those that can tolerate the adverse events. In fact, the adverse event of diarrhea is somewhat severe, but luckily, most of that risk was mediated with appropriate prophylaxis regimen. It perhaps would have contraindications for those with extreme inflammatory bowel or related disorders. FDA-related large scale manufacturing risks and regulatory hurdles could prove to add delays and pitfalls to Puma's terrain, and since this is the only revenue-maker in its pipeline, a lot hinges on its expeditious advancement. However, given the aggressive stance at FDA to get life-saving therapies available to patients, most regulatory risks are ameliorated. Partnership decisions will be important inflection points moving forward.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read more:
Puma Stalks Up - Puma Biotechnology, Inc. (NYSE:PBYI) | Seeking ... - Seeking Alpha

A team of researchers at the University of Melbourne has used a quantum probe to perform microwave-free NMR at the nanoscale.

Researchers at the University of Melbourne have demonstrated a way to detect nuclear spins in molecules non-invasively, providing a new tool for biotechnology and materials science.

Important research in medicine and biology relies on nuclear magnetic resonance (NMR) spectroscopy, but until now, it has been limited in spatial resolution and typically requires powerful microwave fields. A team of researchers at the University of Melbourne has used a quantum probe to perform microwave-free NMR at the nanoscale.

This quantum probe delivers a dramatic improvement in NMR technology. In addition to being able to detect NMR in far smaller samples than conventional machines, the technique does not require the application of microwave fields that might disrupt biological samples.

The discovery may overcome significant limitations with conventional NMR methods, which depend on machines that can exceed 10 tonnes.

With these advances in quantum sensing technology, doors can open to a new world of scientific investigation that could lead us to gain a better understanding of the smallest building blocks of life.

See the rest here:
Researchers in Melbourne provide new biotechnology tool - BSA bureau (press release)

Shares in Prana Biotechnology (NADSAQ:PRAN) surged 19% and was earlier higher in New York as it said an article about early data on PBT434 had been accepted in a peer review journal.

The article deals with the fact the compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsons disease.

Dr David Stamler, Pranas chief medical officer, said: These findings are important because Parkinsons disease and the related synucleinopathies cause significant disability and diminish the independence of afflicted individuals.

"An agent which slows disease progression could have a great impact on reducing disease burden and improving quality of life. We are eager to begin clinical testing of PBT434.

The publication is the culmination of ten years of research from scientists at the Florey Institute of Neuroscience and Mental Health, (Melbourne, Australia), investigating compounds from Prana Biotechnologys propriety chemical library.

Not only was PBT434 shown to block alpha-synuclein accumulation, but it also prevented loss of nerve cells in the region of the brain primarily affected in Parkinsons disease.

To investigate the therapeutic potential of PBT434 to slow neurodegeneration, the researchers performed extensive animal testing in multiple Parkinsons disease models, including tests in mice that over-expressed the alpha-synuclein protein.

These results showed that PBT434 lowered alpha-synuclein and its toxic effects and simultaneously improved motor performance.

Shares added 19% to $2.73.

Original post:
Prana Biotechnology shares surge after journal publication - Proactive Investors UK

SAN ANTONIO, TEXAS--(Marketwired - June 30, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, 2017 in Toronto, Ontario, Canada. This year's Meeting had extraordinary participation from Nerium's shareholders, with a total of 31,272,131 common shares, or approximately 85.75% of the outstanding common shares of Nerium, having been voted at the Meeting.

We are pleased to announce that Nerium's shareholders voted to elect all six of Nerium's director nominees to the board of directors (the "Board"). Each Nerium director nominee received at least 77% of the votes cast by shareholders present in person or represented by proxy at the Meeting. The dissident's director nominees each received 20% of the votes cast by shareholders, which includes the 7.48% of the votes cast by the dissident shareholders. The voting results of the election of directors are as follows:

"We thank Nerium's shareholders for their consideration and support during this process," said Richard Boxer, Chair of the Special Committee of Nerium's Board. "We are pleased that the Company's shareholders voted overwhelmingly to reject the dissident's nominees and elect all of Nerium's nominees to the Board. Your directors will continue to act in the best interests of Nerium and all of its shareholders, and are committed to addressing legitimate shareholder concerns. We intend to provide shareholders with a more detailed update on the Company's business in the coming weeks."

All other matters set out in the Company's management information circular were approved by the requisite majority of the shareholders at the Meeting.

About Nerium Biotechnology, Inc.

Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.

Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at http://www.sedar.com.

Excerpt from:
Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nominees to Nerium's Board - Marketwired (press release)

Biotechnology varieties of corn and soybeans make up 95 percent of the 15.5 million acres planted this spring by Nebraska farmers, according to a report from the USDAs National Agricultural Statistics Service on Friday.

According to the report, Nebraska corn growers planted 9.8 million acres, down 1 percent from last year. Biotechnology varieties were used on 96 percent of the area planted, up 1 percentage point from a year ago. Growers expect to harvest 9.5 million acres for grain, which is down 1 percent from last year.

Statewide, soybean planted area is estimated at 5.7 million acres, up 10 percent from last years total and a record high. Of the acres planted, 94 percent were planted with genetically modified, herbicide resistant seed, down 2 percentage points from a year ago. Acres expected to be harvested are 5.65 million, up 10 percent from a year earlier.

Last year, Nebraska ranked sixth in the nation in harvested acres of principal crops at 19,223,000 acres.

Nationwide, the USDA reported that corn planted area for all purposes in 2017 is estimated at 90.9 million acres, down 3 percent from last year. Compared with last year, planted acres are down or unchanged in 38 of the 48 estimating states. Area harvested for grain, at 83.5 million acres, is down 4 percent from last year.

Soybean planted area for 2017, nationwide, is estimated at a record high 89.5 million acres, up 7 percent from last year. Compared with last year, planted acreage intentions are up or unchanged in 24 of the 31 estimating states.

The USDA reported that winter wheat seeded in the fall of 2016 totaled 1.11 million acres, down 19 percent from last year and a record low. Harvested acreage is forecast at 1 million acres, down 24 percent from a year ago.

Along with declining wheat acres, Nebraska wheat farmers are also having to deal with a wheat virus outbreak that has reached epidemic levels and has been damaging fields and yields in the southern Nebraska Panhandle, according to the Associated Press. The Nebraska Wheat Association earlier this month reported that as many as 85 percent of southern Panhandle fields have been affected by the virus.

Nationwide, all wheat planted area for 2017 is estimated at 45.7 million acres, down 9 percent from 2016. This represents the lowest all wheat planted area on record since records began in 1919. The 2017 winter wheat planted area, at 32.8 million acres, is down 9 percent from last year. Of this total, about 23.8 million acres are hard red winter.

For other Nebraska crops, the USDA reported that:

Alfalfa hay acreage to be cut for dry hay is at 770 thousand acres, up 3 percent from 2016. Other hay acreage to be cut for dry hay is 1.70 million acres, unchanged from last year.

Sorghum acreage planted and to be planted, at 140 thousand acres, is down 30 percent from a year ago. The area to be harvested for grain, at 110 thousand acres, is down 37 percent from last year.

Oats planted area is estimated at 115 thousand acres, down 15 percent from the previous year. Area to be harvested for grain, at 25 thousand acres, is unchanged from a year ago.

Dry edible bean planted acreage is estimated at 150 thousand acres, up 9 percent from last year. Harvested acres are estimated at 139 thousand acres, up 14 percent from the previous year.

Proso millet plantings of 130 thousand acres are up 37 percent from a year ago.

Sugarbeet planted acres, at 49.7 thousand, are up 4 percent from last year.

Oil sunflower acres planted are estimated at 55 thousand, up 90 percent from last year. Non-oil sunflower planted acreage is estimated at 6 thousand acres, down 52 percent from a year ago and a record low.

Dry edible pea estimated planted acres are 45 thousand acres, down 18 percent from last year. Harvested acres are estimated at 42 thousand, down 19 percent from the previous year.

See the article here:
Biotechnology crops dominate Nebraska crop fields - Grand Island Independent

Biotechnology Separation Systems Market

Overview

The report on the Global Biotechnology Separation Systems Market 2017 gives complete view of the market across the globe. In-depth analysis comprising key market players, market forecasts, supply, demand, profit, latest market trends, and many more are provided in the report below. The future aspects impacting the global market in every possible way are also further discussed in the report.

What our report offers:

View Free Sample Report @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#RequestSample

Biotechnology Separation Systems Market: Research methodology

To Know More, Ask Our Expert @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#InquiryForBuying

Additional information provided in the report

In addition, considering that the global economy is ever-changing depending upon several factors , it is important to take a note that our report contains data that are not only conducted regarding CAGR forecasts but it also analyzes the key parameters such as yearly market growth in order to have complete information about the future of the market worldwide. It also helps in identifying the wide opportunities that will open up for the market. The other key feature included in this report is the analysis of the revenue forecasts of all the important regions and applications, which is in terms of dollars.

About Market research Store

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:

Joel John 3422 SW 15 Street, Suit #8138, Deerfield Beach, Florida 33442, USA USA Tel: +1-386-310-3803 GMT Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@marketresearchstore.com Web: http://www.marketresearchstore.com/

Read this article:
Biotechnology Separation Systems Market 2017 Industry Analysis ... - World Of WallStreet

The Economic and Financial Crimes Commission, EFCC, says it has arrested Lucy Ogbadu, the Director-General of National Biotechnology Development Agency (NABDA), over alleged N23 million fraud.

The spokesperson of the commission, Wilson Uwujaren, disclosed this in a statement he issued on Thursday.

Mr. Uwujaren said Ms. Ogbadu was picked up by EFCC operatives in Port Harcourt on Wednesday, following her alleged link with the Bayelsa State Director of Bio-resources Development Centre, Josiah Habu.

Mr. Habu, according to him, is being investigated by the anti-graft agency in a case of fraudulent diversion of N75 million.

He said investigations by the EFCC revealed that Ms. Ogbadu allegedly received N23 million through a bank account belonging to the wife of Mr. Habu, Esther Habu.

The EFCC spokesperson stated that Ms. Ogbadu admitted the transaction in a voluntary statement made to the commissions investigators.

Further investigations also revealed that Mrs Habu is one of the contractors with Bio-resources Development Centre, Odi, Bayelsa State.

A total of N603 million has been traced to her in different deals involving over 20 directors of the centre across the country.

Ogbadus involvement is being investigated. She has been duly served with bail conditions while investigations continue, Mr. Uwujaren added.

Ms. Ogbadu, a professor of microbiology, was appointed NABDA director-general in November 2013.

(NAN)

Continued here:
Director General of Nigeria's biotechnology agency arrested over ... - Premium Times

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

Read more:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Newswise Industrial biotechnology scientists, educators, entrepreneurs and executives from around the globe will be convening on the University of California San Diego campus this summer to explore the latest advances and world-changing innovations heating up the white-hot field of industrial biotechnology with workshops in microbial fermentation and metabolic engineering.

UC San Diego Extension will host its annual Industrial Biotechnology Workshops on Aug. 14 through 18. Participants can attend the whole program or attend the workshops on microbial fermentation or metabolic engineering separately.

Now in its fifth year, this widely acclaimed educational event creates an informal, intimate environment for robust exchange of knowledge and ideas among world-class academic instructors and leaders of cutting-edge companies of every size from startup to mature, said Hugo Villar, associate dean of Professional & Continuing Education for UC San Diego Extension.

Whether from California or China, biotechnology professionals attending these workshops will have a front-row seat to learn about current developments and advanced scientific skills being used to solve some the worlds most difficult problems, Villar said.

Microbial Fermentation

For the past four years, the workshop focused primarily on microbial fermentation, which is the transformation of feedstocks, such as plant sugars, into useful products, like fuels, chemicals, beer or antibiotics, by bacteria, yeast, fungi or algae.

The Microbial Fermentation Workshop will be held Aug. 16 to 18. Participants will be introduced to the fundamental knowledge and practical skills needed to design, develop, optimize, control, scale-up, analyze and troubleshoot fermentation processes.

As one of just a handful of programs in the world that provide in-depth, practically oriented coursework in microbial fermentation, it is expected to draw participants from Connecticut to Croatia.

While workshop participants should have some basic knowledge and experience in fermentation, everyone from scientists to biotech business executives to graduate students could benefit from the microbial fermentation workshop.

This years program features some of the brightest minds in the field, including:

Jeff Lievense, senior advisor of Bioengineering & Technology, Genomatica;

Rachel Dutton, assistant professor of Molecular Biology, UC San Diego;

Michael Japs, senior director of Process Technology, Genomatica;

Jon Hansen, principal of New Leaf Biotech;

Jason Ryder, vice president, Process R&D, Hampton Creek; and

Karen Fortmann, senior research scientist, White Labs.

Five interactive case studies, including production of microbes for cheese and beer, will allow attendees to practice what they learn, while the Fermentation Firing Line segment will offer a lively, open ended forum for posing questions to the instructional team on fermentation-related topics.

In addition, everyone in attendance can participate in a tour of the global headquarters of White Labs, which produces yeast for beer making, and attend a hosted reception in its craft beer tasting room.

Metabolic Engineering

A new segment on metabolic engineering, which will run Aug. 14-15, will also be offered.

Recently named as one of the top 10 emerging technologies by the World Economic Forum, metabolic engineering focuses on the design and development of equipment and processes for manufacturing products such as agriculture, food, animal feed and pharmaceuticals.

Instructors joining the interactive course with case studies throughout the curriculum include:

John Pierce, MIT lecturer and former scientist at multinational firms BP and DuPont;

Adam Feist, project scientist, UC San Diego;

Ben Griffin, senior director, Microbial and Enzyme Engineering, Synthetic Genomics;

Jeff Lievense, senior advisor, Genomatica;

Jim Mills, chief technology officer, BioAmber, Inc.;

Bernhard Palsson, principal investigator, UC San Diego; and

Kristy Salmon, head of research, BP.

Those who attend the Metabolic Engineering segment are also invited to participate in a tour of the global headquarters of White Labs, which produces yeast for beer making, and attend a hosted reception in its craft beer tasting room.

Those interested in finding out more about the upcoming workshops can visit http://extension.ucsd.edu/industrialbiotech , call (858) 534-9353 or email unexbio@ucsd.edu.

Read more from the original source:
Explore Innovations in Industrial Biotechnology at Upcoming ... - Newswise (press release)

Press articles about Puma Biotechnology (NYSE:PBYI) has been popular fairly negative last few days, Accern reports. The analytics team pointing out the bullish and bearish news analysis by observing larger than 20 Million public financial documents, market websites and SEC sources in real-time. Accern grades analysis of public companies ranging from -1 to 1, with ranks nearest to 1 is considered more positive. Puma Biotechnology achieved a news impact rank of -0.01 on Accerns range. Accern issued stories about the biopharmaceutical company a media impact point of 66 out of 100, pointing that recent news analysis is likely to impact the share value upcoming future.

Puma Biotechnology (NYSE:PBYI) previously disclosed its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) Earnings per share for the period, reaching the Thomson Reuters average forecast of ($2.06) by $0.09. Brokerage firms predict that Puma Biotechnology to post ($8.50) earnings per share for the full year.

Puma Biotechnology (NYSE:PBYI) transacted up 4.71% throughout intraday market trading on early Wed, topping $88.85. the share had a trading volume of 872,030 Stocks. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00. The stocks market valuation is $3.28 B. Companys 50 Day SMA is $59.74 and its 200 day SMA is $42.39.

PBYI has been the topic of many Study analysis. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 target price for The corporation in a study note on Sunday, May 28th. Zacks Lowered Puma Biotechnology from a buy recommendation to a hold recommendation in a analysis note on early Wed, Jun 14th. Stifel Nicolaus reiterated a buy recommendation and fixed a $105.00 target price on stock of Puma Biotechnology in a study note on early Mon, Jun 5th. J P Morgan Chase & Co reissued an overweight recommendation and fixed a $89.00 target price on stock of Puma Biotechnology in a study note on early Tue, Jun 6th. Lastly, Royal Bank Of Canada boosted their target price on Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis note on Tue, Jun 6th. 1 investment expert has recommended the share with a sell recommendation, two have published a hold recommendation and six have published a buy recommendation to The corporation. Puma Biotechnology currently has a average recommendation of Buy and an consensus price target of $86.94.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade on early Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a transaction filed with the securities and exchange commission, which is available through the Security and Exchange Commission website. executive have unloaded 1,990,088 stocks of company shares valued $157,553,113 during the last ninety days. Executives own 22.70% of the firms stock.

Original post:
Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis - Insider Tradings